Your browser doesn't support javascript.
loading
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander, M; Olsson-Strömberg, U; Schlums, H; Guilhot, J; Brück, O; Lähteenmäki, H; Kasanen, T; Koskenvesa, P; Söderlund, S; Höglund, M; Markevärn, B; Själander, A; Lotfi, K; Dreimane, A; Lübking, A; Holm, E; Björeman, M; Lehmann, S; Stenke, L; Ohm, L; Gedde-Dahl, T; Majeed, W; Ehrencrona, H; Koskela, S; Saussele, S; Mahon, F-X; Porkka, K; Hjorth-Hansen, H; Bryceson, Y T; Richter, J; Mustjoki, S.
Afiliación
  • Ilander M; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Olsson-Strömberg U; Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Schlums H; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Guilhot J; Centre for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Brück O; Institut National de la Sante' et de la Recherche Medicale (INSERM), CHU de Poitiers, Poitiers, France.
  • Lähteenmäki H; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Kasanen T; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Koskenvesa P; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Söderlund S; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Höglund M; Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Markevärn B; Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Själander A; Department of Hematology, Umeå University Hospital, Umeå, Sweden.
  • Lotfi K; Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
  • Dreimane A; Department of Hematology, Linköping University Hospital, Linköping, Sweden.
  • Lübking A; Department of Hematology, Linköping University Hospital, Linköping, Sweden.
  • Holm E; Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden.
  • Björeman M; Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden.
  • Lehmann S; Department of Hematology, University Hospital, Örebro, Sweden.
  • Stenke L; Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Ohm L; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Gedde-Dahl T; Department of Medicine, Division of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Majeed W; Department of Medicine, Division of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Ehrencrona H; Department of Medicine, Division of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Koskela S; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Saussele S; Department of Hemato-oncology, Stavanger University hospital, Stavanger, Norway.
  • Mahon FX; Department of Clinical Genetics, Skåne University Hospital, Lund, Sweden.
  • Porkka K; Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland.
  • Hjorth-Hansen H; III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.
  • Bryceson YT; Inserm U1035, Université Bordeaux Segalen, Bordeaux, France.
  • Richter J; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Mustjoki S; Department of Hematology, St Olavs University Hospital, Trondheim, Norway.
Leukemia ; 31(5): 1108-1116, 2017 05.
Article en En | MEDLINE | ID: mdl-27890936
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Leucemia Mielógena Crónica BCR-ABL Positiva / Mesilato de Imatinib Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Finlandia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Leucemia Mielógena Crónica BCR-ABL Positiva / Mesilato de Imatinib Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Finlandia